USFDA issues 13 observations after inspection of Lupin arm’s facility in US

Drug firm Lupin on Monday said the US health regulator has issued 13 observations after inspection of its subsidiary’s Somerset facility in New Jersey.

In a regulatory filing, Lupin said the inspection by US Food and Drug Administration (USFDA) commenced on September 10, 2020, and concluded on November 5, 2020. The duration of the inspection was prolonged due to COVID-related delays and challenges.

The inspection has closed with 13 observations, it said.

“We are confident of addressing these observations and will work closely with the agency to address their concerns,” the company said.

Lupin said it does not believe that this will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The facility contributes less than 5 per cent of our global revenues, it added.

Shares of Lupin were trading 0.52 per cent lower at Rs 911.60 apiece on BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor